BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/8/2022 2:31:10 AM | Browse: 463 | Download: 1143
 |
Received |
|
2022-01-14 08:11 |
|
Peer-Review Started |
|
2022-01-14 08:12 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-04-18 00:27 |
|
Revised |
|
2022-04-18 15:00 |
|
Second Decision |
|
2022-05-23 03:28 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-28 07:03 |
|
Articles in Press |
|
2022-05-28 07:03 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-05-31 07:38 |
|
Publish the Manuscript Online |
|
2022-06-08 02:31 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Retrospective Study |
| Article Title |
Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chrong-Reen Wang and Hung-Wen Tsai |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Chrong-Reen Wang, MD, PhD, Full Professor, Department of Internal Medicine, National Cheng Kung University Hospital, No. 138 Sheng-Li Road, Tainan 70403, Taiwan. wangcr@mail.ncku.edu.tw |
| Key Words |
Insulin resistance; Rheumatoid arthritis; Diabetes mellitus; Tofacitinib; Janus kinase inhibitor |
| Core Tip |
An increased risk of insulin resistance (IR) has been identified in rheumatoid arthritis (RA), a chronic inflammatory disorder with elevated levels of pathogenic cytokines. In addition to controlling RA activity, biologics targeting proinflammatory cytokines have been shown to reduce IR, while it remains to be elucidated whether Janus kinase inhibitor therapy can cause IR reduction in such patients. This retrospective study carried out in non-diabetic active RA patients classified into high-IR and low-IR groups before tofacitinib (TOF) therapy demonstrated reduced IR by 24 wk of TOF treatment in the active RA patients with high baseline IR status. |
| Publish Date |
2022-06-08 02:31 |
| Citation |
Wang CR, Tsai HW. Immediate-release tofacitinib reduces insulin resistance in non-diabetic active rheumatoid arthritis patients: A single-center retrospective study. World J Diabetes 2022; 13(6): 454-465 |
| URL |
https://www.wjgnet.com/1948-9358/full/v13/i6/454.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v13.i6.454 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
